Track topics on Twitter Track topics that are important to you
SAN DIEGO, July 27, 2015 (GLOBE NEWSWIRE) -- Ciclofilin Pharmaceuticals Inc. today announced that its Chief Executive Officer, Dr. Robert T. Foster, will discuss the company's hepatitis B development program for its lead antiviral drug, CPI-431-32, during a presentation at the Jefferies 2015 Hepatitis B Summit. The conference will take place on August 6th at the Boston Harbor Hotel.
Ciclofilin Presentation Details:
Date: Thursday, August 6th, 2015
Time: 9:30 a.m. Eastern Time
Location: Boston Harbor Hotel, North Atlantic Room
Ciclofilin is a privately held life sciences company based in San Diego, California, with R&D facilities in Edmonton, Canada. The company's lead drug, CPI-431-32, is uniquely designed to specifically target the host and not the virus. By targeting the host, CPI-431-32 interferes with the necessary cellular components that allow the virus to infect cells, replicate, and to propagate. CPI-431-32 has more than one mode of action; inhibition of viral transport into cells with additional downstream effects on the virus life cycle. In addition to the anti-HBV effects of CPI-431-32, cyclophilin inhibitors, as a class, may also target liver disease (liver inflammation and fibrosis, liver cirrhosis, and hepatocellular carcinoma).
CONTACT: Investor Contact Ciclofilin Pharmaceuticals, Inc., Dr. Robert T. Foster, CEO, +1 (780) 909-5041; Email: email@example.com Mr. Michael Kamdar, President, +1 (858) 733-1308; Email: firstname.lastname@example.org Media Contact Steve Kilmer, +1 (647) 872-4849; Email: email@example.comNEXT ARTICLE
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...